Environmental, social, and governance (ESG) reporting is no longer optional for peptide and biotech companies. Investors, regulators, and customers all want to see how your company performs on sustainability.
If your company has not started its ESG reporting journey, you are already behind. This guide covers what you need to know to get started and stay compliant.
- ESG reporting is now effectively mandatory for peptide companies seeking institutional investment, with over 75% of investors weighing ESG factors.
- Most peptide companies must report under multiple frameworks, so identify which ones like CSRD, SEC, or SASB apply to your specific operations.
- Peptide manufacturers should prioritize environmental metrics tied to solvent use, energy-intensive synthesis, and Scope 3 emissions across their supply chain.
- Strong social and governance programs attract top biotech talent and create competitive advantages beyond mere regulatory compliance.
- Avoid treating ESG as a marketing exercise or ignoring Scope 3 emissions, which are among the most common and costly reporting mistakes.
- Start with a step-by-step approach to ESG reporting now, as companies that delay risk falling behind on both compliance and access to capital.
Why ESG Matters for Peptide Companies
Peptide and biotech companies face unique ESG challenges. Manufacturing processes involve chemicals, solvents, and energy-intensive synthesis methods that create environmental impact.
Investors are paying close attention. According to PwC's Global Investor Survey, more than 75% of institutional investors consider ESG factors when making investment decisions. This number has risen steadily over the past five years.
The global ESG assets under management are expected to exceed $40 trillion by 2030. Companies that cannot demonstrate strong ESG performance may find it harder to attract capital.
Key ESG Reporting Frameworks
Several frameworks guide ESG reporting. Peptide and biotech companies should understand which ones apply to them.
Major Frameworks Comparison
| Framework | Focus | Mandatory or Voluntary | Relevance to Peptide Industry |
|---|---|---|---|
| EU Corporate Sustainability Reporting Directive (CSRD) | Comprehensive ESG | Mandatory (EU companies and certain non-EU) | High for companies with EU operations |
| SEC Climate Disclosure Rules | Climate risk and emissions | Mandatory (US public companies) | High for US-listed companies |
| Global Reporting Initiative (GRI) | Broad sustainability | Voluntary | Medium to high |
| Sustainability Accounting Standards Board (SASB) | Industry-specific metrics | Voluntary (often expected by investors) | High for biotech/pharma sector |
| Task Force on Climate-Related Financial Disclosures (TCFD) | Climate-related financial risk | Increasingly mandatory | Medium to high |
| International Sustainability Standards Board (ISSB) | Global baseline for sustainability | Becoming mandatory in some jurisdictions | High |
Most large peptide companies will need to report under multiple frameworks. The key is understanding which ones are mandatory for your specific situation.
Environmental Metrics for Peptide Companies
The "E" in ESG is especially important for peptide manufacturers. Peptide synthesis involves processes that have measurable environmental impact.
Key Environmental Metrics to Track
Peptide companies should focus on metrics that reflect their actual environmental footprint. Not all standard environmental metrics are equally relevant to every company.
| Environmental Metric | Why It Matters for Peptide Companies | How to Measure |
|---|---|---|
| Greenhouse gas emissions (Scope 1, 2, 3) | Manufacturing uses significant energy | Carbon accounting protocols |
| Solvent usage and recovery | SPPS uses large volumes of solvents like DMF and NMP | Volume tracking and recovery rates |
| Water consumption | Purification and cleaning processes are water-intensive | Flow meters and water balance |
| Hazardous waste generation | Chemical synthesis creates regulated waste streams | Waste manifests and disposal records |
| Energy intensity per unit produced | Shows efficiency improvements over time | Energy use per gram or per batch |
Solvent usage is a particularly important metric for peptide companies. Solid-phase peptide synthesis can use 5,000 to 10,000 liters of solvent per kilogram of peptide produced.
Sustainability Director, European Peptide CDMO put it plainly: "Peptide companies that invest in solvent recovery and green chemistry will see ESG benefits and cost savings at the same time. Solvent costs are one of the largest variable expenses in peptide manufacturing."
Reducing Environmental Impact
There are practical steps peptide companies can take to improve their environmental performance. These steps also make good business sense.
Solvent recovery systems can recapture 70% to 90% of solvents used in peptide synthesis. This reduces both waste generation and raw material costs.
Switching to greener solvents where possible is another strategy. Research into alternatives to DMF and NMP is advancing, and some peptide manufacturers have already adopted less toxic options for certain process steps.
Social Metrics for Peptide Companies
The "S" in ESG covers how companies treat their employees, communities, and the patients who use their products.
Workforce and Community Metrics
| Social Metric | What to Report | Industry Benchmark |
|---|---|---|
| Employee safety (incident rate) | Lost-time injuries per 200,000 hours worked | < 1.0 for pharma manufacturing |
| Diversity and inclusion | Gender, ethnicity, and role-level breakdowns | Improving year over year |
| Employee turnover | Voluntary and involuntary turnover rates | < 15% for biotech |
| Training and development | Hours of training per employee per year | 40+ hours per year |
| Community engagement | Local hiring, charitable giving, STEM education support | Varies by company size |
| Patient access | Pricing programs, compassionate use, geographic availability | Industry-specific benchmarks |
Employee safety is critical in peptide manufacturing. Workers handle chemicals, operate complex equipment, and work in cleanroom environments that all carry safety risks.
The ongoing biotech workforce shortage makes social metrics even more important. Companies with strong ESG social scores find it easier to attract and retain talent.
Building a Strong Social Program
Start by measuring where you are today. Many peptide companies do not have baseline data for key social metrics, which makes improvement hard to demonstrate.
Set clear targets and report on them annually. Transparency about both successes and areas for improvement builds trust with investors and employees.
Governance Metrics for Peptide Companies
The "G" in ESG covers how companies are managed and governed. Strong governance reduces risk and builds investor confidence.
Key Governance Metrics
| Governance Metric | What Investors Look For | Best Practice |
|---|---|---|
| Board diversity | Gender, ethnicity, and expertise diversity on the board | At least 30% women, range of backgrounds |
| Executive compensation alignment | Pay tied to long-term performance and ESG goals | Include ESG metrics in bonus structures |
| Ethics and compliance | Code of conduct, anti-corruption policies, whistleblower protection | Comprehensive program with regular training |
| Supply chain oversight | Due diligence on CDMO and supplier ESG practices | Regular audits and corrective action processes |
| Data privacy and security | Protection of clinical trial data and patient information | SOC 2 or ISO 27001 certification |
| Intellectual property management | Patent strategy and trade secret protection | Regular IP audits and portfolio reviews |
Supply chain governance is especially relevant for peptide companies. Many drug sponsors rely on CDMOs for manufacturing, which means their ESG performance is partly tied to their partners' practices.
More than 60% of institutional investors now include supply chain ESG risk in their due diligence when evaluating biotech investments. Your CDMO's ESG performance can affect your own ESG rating.
Regulatory Requirements by Region
ESG reporting requirements vary significantly by region. Peptide companies with global operations need to navigate multiple regulatory regimes.
EU Requirements
The EU's Corporate Sustainability Reporting Directive (CSRD) is the most comprehensive ESG reporting mandate in the world. It applies to large EU companies and non-EU companies with significant EU revenue.
CSRD requires detailed reporting on environmental, social, and governance topics. Reports must be audited by an independent third party.
US Requirements
The SEC's climate disclosure rules require US public companies to report on climate-related risks and greenhouse gas emissions. These rules took effect in phases starting in 2024.
While less broad than the CSRD, the SEC rules still require significant data collection and reporting infrastructure. Private peptide companies are not directly subject to these rules but may face pressure from investors.
Asia-Pacific Requirements
ESG reporting requirements in Asia-Pacific vary by country. Japan, Hong Kong, and Singapore have introduced mandatory or comply-or-explain ESG reporting for listed companies.
India requires the top 1,000 listed companies to file Business Responsibility and Sustainability Reports. China is developing its own ESG disclosure standards.
Getting Started with ESG Reporting
If your peptide company is just beginning its ESG journey, here is a practical roadmap.
Step-by-Step Approach
Start with a materiality assessment. This process identifies which ESG topics are most important to your stakeholders and your business.
Next, establish baseline measurements for your key metrics. You cannot improve what you do not measure.
Then, set realistic targets and build the internal systems needed to track and report on them. Consider investing in ESG data management software to streamline this process.
Finally, publish your first ESG report. It does not need to be perfect. Investors value transparency and a clear commitment to improvement over polished reports with no substance.
The Business Case for ESG in Peptide Companies
ESG is not just about compliance. There is a strong business case for taking ESG seriously.
Financial Benefits
Companies with strong ESG performance often enjoy lower cost of capital. Investors see them as lower risk, which translates to better financing terms.
ESG improvements in areas like energy efficiency and waste reduction also deliver direct cost savings. Green chemistry initiatives in peptide manufacturing can reduce raw material costs by 10% to 20%.
Competitive Advantages
Drug sponsors are increasingly selecting CDMOs based partly on ESG criteria. Strong ESG performance can be a differentiator in winning new contracts.
Companies that stay ahead of the pharmaceutical outsourcing trends related to ESG will capture business from competitors who lag behind.
Talent Attraction
Younger workers especially care about working for companies with strong ESG commitments. In a tight labor market, ESG performance can tip the scale when candidates are choosing between offers.
Studies show that companies with strong ESG reputations receive 25% more applications for open positions. In a market with severe talent shortages, this advantage is significant.
Common ESG Reporting Mistakes
Avoid these common pitfalls as you build your ESG reporting program.
Greenwashing
Making ESG claims that are not backed by data is worse than not reporting at all. Regulators and investors are getting better at spotting greenwashing, and the consequences can be severe.
Stick to what you can measure and verify. Be honest about areas where you need to improve.
Ignoring Scope 3 Emissions
Many peptide companies focus only on direct emissions (Scope 1) and energy-related emissions (Scope 2). But investors increasingly want to see Scope 3 emissions, which include your entire supply chain.
For peptide companies, Scope 3 often includes raw material production, logistics, and waste disposal. These can be significant and should not be ignored.
Treating ESG as a Marketing Exercise
ESG reporting should be driven by genuine commitment to improvement, not by marketing goals. Companies that treat ESG as a check-the-box exercise will eventually be exposed.
Build ESG into your business strategy, not just your communications. When ESG goals align with business goals, the results are more authentic and more durable.
Frequently Asked Questions
Do private peptide companies need to do ESG reporting?
Private companies are not always subject to mandatory ESG reporting rules. However, many private companies choose to report voluntarily because investors, customers, and partners increasingly expect it.
What ESG framework should a peptide company use?
Start with SASB standards for the biotechnology and pharmaceuticals industry. These provide industry-specific metrics that are relevant and practical. Add CSRD compliance if you have EU operations.
How much does ESG reporting cost?
Costs vary widely depending on company size and reporting scope. Small companies can start with $50,000 to $100,000 for initial setup and first-year reporting. Larger companies may invest $500,000 or more annually.
What are the most important environmental metrics for peptide manufacturers?
Solvent usage and recovery rates, greenhouse gas emissions, water consumption, and hazardous waste generation are the most important environmental metrics for peptide manufacturing operations.
How do ESG requirements affect CDMOs?
CDMOs are increasingly expected to meet ESG standards set by their drug sponsor customers. Strong ESG performance can be a competitive advantage in winning and retaining CDMO contracts.
Can ESG improvements actually save money?
Yes. Energy efficiency, solvent recovery, waste reduction, and other ESG-related improvements often deliver direct cost savings. Many peptide companies find that ESG investments pay for themselves within two to three years.
The Road Ahead
ESG reporting for peptide and biotech companies will only become more important. Regulatory requirements are expanding, investor expectations are rising, and customers are asking tougher questions.
Companies that embrace ESG as a core business practice will build stronger businesses, attract more capital, and win more customers. The time to start is now.
Topics
Dr. Sarah Chen
Clinical Operations Director
PhD Biochemistry | 14 years in peptide therapy operations
Specializes in clinical workflow design and regulatory compliance for peptide therapy practices, with direct experience managing multi-site compounding operations and FDA audit readiness.
Reviewed by Dr. Sarah Chen, PhD, April 2026